Spark xyz

Nob Hill Therapeutics

Nob Hill Therapeutics, Inc. (NHT) is developing new technologies and therapies for lung-related diseases that can’t be effectively treated today, including the world's first dry powder nebulizer which is used to deliver high doses of medicine directly to the lungs for the effective treatment of several lung-related diseases. These diseases impact millions of patients, and the annual market potential for several of these diseases is substantial (e.g., lung cancer - $30b, Cystic Fibrosis - $13b, Invasive fungal infections - $9b).

Albuquerque, NM, USA

One Liner: Nob Hill Therapeutics, Inc. (NHT) is developing new technologies and therapies for lung-related diseases that can’t be effectively treated today, including the world's first dry powder nebulizer which is used to deliver high doses of medicine directly to the lungs for the effective treatment of several lung-related diseases. These diseases impact millions of patients, and the annual market potential for several of these diseases is substantial (e.g., lung cancer - $30b, Cystic Fibrosis - $13b, Invasive fungal infections - $9b).

Problem: Many diseases (e.g., lung infections, lung cancer, Cystic Fibrosis) cannot be treated well because today’s inhalation technologies cannot efficiently deliver high doses of medicine to the lungs. The resulting impact on the US healthcare system exceeds $1b for many diseases. Patients remain sick, live with side effects, and must endure regular hospital visits.

For example, there are 250 million lower respiratory infection cases every year, the 5th leading cause of death in the world. The multidrug resistance infections are hard to treat, require long periods and large dose of antibiotics, which lead to severe and intolerable side effects. There are unmet needs for these patients to have targeted therapies that can directly deliver drugs to the site of respiratory infections. Currently available inhaled options for the treatment of lung infections are limited primarily by suboptimal delivery: low therapeutic dose loading, long treatment session, difficult to use, and can't be used in patients with poor lung function.

About Us: Nob Hill Therapeutics, Inc. (NHT) is developing new technologies and therapies for lung-related diseases that can’t be effectively treated today. Nob Hill has developed a novel drug inhalation device platform (the world's first dry powder nebulizer) that solves many disadvantages with today’s technologies. NHT is also working on developing accompanying drug-device combination products that will serve as PoC for the technology (with addressable US markets of $1.75b annual sales). The company plans to partner with pharma companies that can use the technology to develop a range of drug-device combination products that encompass the delivery technology.

Highlights: Large potential markets
-$15b inhalation drug delivery market; 2 products initiated with $1.75b US addressable markets
-Other disease states with large potential markets (e.g., cystic fibrosis - $13b)

Technology (DryNeb) with a unique value proposition – gets more medicine to the lungs
-Exclusive license to IP (4 patents); NHT also filed own IP

Strategic partners: Gaining traction with several potential partners; signed NHT’s first MTA which will provide the company's first revenue

Team: Strong leadership team and Advisory Board with 100+ years relevant experience

Non-dilutive funding: Won three SBIR grants ($4m)

Exit: Multiple exit opportunities by 2025 ($150m+ for each event)

Funding: Series A preferred equity. $3m. First close of the round is complete

Other
-MedTech top 10 drug delivery solutions provider in 2022
-Posters at several conferences: DDL, ATS, ERS, etc.

Business Model: Early revenue: Device platform licensing and co-development of respiratory combination products
Combination therapy products pipeline development and prepare for M&A or licensing event

Quote: Nob Hill Therapeutics' Dry Powder Nebulizer platform removes the limitations of liquid nebulizers and DPIs. Overall, our device platform is the world's first inhalation device that can be combined with a therapeutic to
-Deliver high doses of medicine directly to the lung...
-In 1-2 minutes of administration time…
-While the patient breathes normally...
-Without a need for a special formulation

Plus, the device platform…
Can be customized depending on the medicine characteristics
Is small (size of your phone)
Is easy to maintain

We have an exclusive license for multiple patents on the technology.

Revenue To Date

N/A

MRR

N/A

Revenue YTD

N/A

Burn Rate

$50K

Total Users

N/A

Total Users (Past 30 Days)

N/A

Daily Active Users

N/A

Monthly Active Users

N/A

Total Paying Users

N/A

MoM Growth Users

N/A

Organic Traffic %

N/A

CAC

N/A

LTV

N/A

Churn

N/A

Margins

N/A

Business Strategy: Licensing the technology platform to multiple pharma companies through co-development and commericalization agreements. Additionally, take two drug device combination products (which repurpose existing medicines) through clinical I/II and then sell or license them. Note that the US addressable market for our first combination product (anti-fungal) is $500m and the second (anti-cancer) is $1.25b. The overall inhaled drug delivery market is $15b.

Competitive Analysys: While there are many inhalation technologies (and device manufacturers) on the market, none of them can deliver high doses of medicine to the lungs as efficiently as Nob Hill’s technology. On the therapy front, there are a few companies trying to develop lung-focused anti-fungals (e.g., Pulmocide, Pulmmatrix), but these may not address our specific disease state and/or have issues (e.g., special formulation, use of an azole which is known to have issues with resistance). Currently, there are few (if any) good lung cancer agents.

Furthermore, Nob Hill's delivery platform has IP that covers a broad range of therapeutic opportunities. By combining the patented technology with drugs that have known (proven) clinical outcomes the product development costs are lower. By utilizing known third party expertise in this space (who have done this before) we can move quickly based on prior product development experience. Picking indications with FDA Fast Track path and clinical outcomes with clearly defined end points will be key, hence we have developed a world class Advisory Board.

Competitor	Website
Pulmocide	pulmocide.com
philips	www.philips.com
novartis	www.novartis.com

Networking: We are open to meeting up to grab a coffee, or just to chat. We would really enjoy your feedback and insight into our venture and would be happy to discuss anything that you are currently working on to see if we can be of service!

Name	Amount
Amount Left	$1,300,000.00
Amount Raised (This Round)	$1,700,000.00
Amount Raise To Date	$5.08M
Investment Type	N/A
Type of Raise	Preferred equity

Valuation

N/A

Seed Bridge

$1.08M

Grant Dollars Awarded

$4M

TAM

N/A

SAM

N/A

SOM

N/A

Business Stage: Series A

Business Types: Investor-Backed

B2B2C

Technology

Healthcare

Biotechnology

Nob Hill Therapeutics

One Liner

What Problem We are Solving

About Us

Venture Highlights

Business Model

Competitive Advantage

Revenue

Users

Customer Costs

Go-To Market Strategy

Team

Competitive Analysis

Networking

Share

Capital

TAM SAM SOM

Business Stage

Business Type

Categories